Germ cell tumors: Review of selected studies from 2002

Current Opinion in Oncology

Volumn 15, Issue 3, 2003, Pages 234-238

  Hellerstedt, Beth A ^a   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Box 0946 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; MOLECULAR GENETICS; MUCOSA INFLAMMATION; NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GERMINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0038010427     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200305000-00010     Document Type: Review

References (32)

1. Olsson HL, Bladstrom A, Alm P: Gynecomastia and risk for malignant tumors - a cohort investigation. BMC Cancer 2002, 2:26.
2. Cast JEI, Nelson WM, Early AS, et al.: Testicular microlithiasis: prevalence and tumor risk in a population referred for scrotal sonography. AJR Am J Roentgenol 2000, 175:1703-1706.
3. Middleton WD, Teefey SA, Santillan CS: Testicular microlithiasis: prospective analysis of prevalence and associated tumor. Radiology 2002, 24:425-428. An important prospective analysis of the association of microlithiasis with cancer.
4. Bennett HF, Middleton WD, Bullock AD, et al.: Testicular microlithiasis: US follow-up. Radiology 2001, 218:359-363.
5. Hartmann JT, Nichols CR, Droz JP, et al.: Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002, 13:1017-1028.
6. Shahidi M, Norman AR, Dearnaley DP, et al.: Late recurrence in 1263 men with testicular germ cell tumors. Cancer 2002, 95:520-530.
7. Kollmannsberger C, Mayer F, Pressler H, et al.: Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 2002, 95:301-308.
8. Soule S, Baldridge L, Kirkpatrick K, et al.: Her-2/neu expression in germ cell tumors. J Clin Pathol 2002, 55:656-658.
9. Mayer F, Gillis AJM, Dinjens W, et al.: Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002, 62:2758-2760.
10. Mueller E, Sarraf P, Tontonoz P, et al.: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998, 1:465-470.
11. Sarraf P, Mueller E, Jones D, et al.: Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998, 4:1046-1052.
12. Chang TH, Szabo E. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Cancer Res 2000, 60:1129-1138.
13. Hase T, Yoshimura R, Mitsuhashi M, et al.: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 2002, 60:542-547.
14. Kollmannsberger C, Oechsle K, Dohmen BM, et al.: Prospective comparison of 18F Fluorodeoxyglucose positron emission tomography with convention assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002, 94:2353-2362.
15. Bokemeyer C, Kollmannsberger C, Oechsle K, et al.: Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using 18F FDG PET. Br J Cancer 2002, 86:506-511.
16. Gietema JA, Meinardi MT, Sleijfer DT, et al.: Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002, 13:1616-1620. CXR may not be an important part of follow-up in post-chemotherapy patients achieving CR, limiting further radiation exposure and cost.
17. Ohyama C, Chiba Y, Yamazaki T, et al.: Lymphatic mapping and gamma probe guided laparoscopic biopsy of sentinel lymph node in patients with clinical stage I testicular tumor. J Urol 2002, 168:1390-1395. Sentinel lymph node mapping may provide even further refinement of therapy with minimal surgical risk.
18. Spermon JR, Roeleveld TA, van der Peel HG: Comparison of surveillance and retroperitoneal lymph node dissection in stage I non-seminomatous germ cell tumors. Urology 2002, 59:923-929. Recent data on the potential for surveillance in patients with stage I NSGCT, even with unfavorable prognostic features.
19. Hendry WF, Norman AR, Dearnaley DP, et al.: Metastatic nonseminomatous germ cell tumors of the testis. Results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002, 94:1668-1676.
20. Kollmannsberger C, Rick O, Klaproth H, et al.: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 2002, 87:729-732.
21. Miki T, Mizutani Y, Nonomura N, et al.: Irinotecan plus cisplatin has substantial antitumor effect as a salvage chemotherapy against germ cell tumors. Cancer 2002, 95:1879-1885.
22. Motzer RJ, Bajorin DR, Schwartz LH, et al.: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994, 12:2277-2283.
23. Nazario A, Amato R, Hutchinson L, et al.: Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urol Oncol 1995, 1:184-187.
24. Bokemeyer C, Beyer J, Metzner B, et al.: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996, 7:31-34.
25. Sandler AB, Cristou A, Fox S, et al.: A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 1998, 82:1381-1386.
26. Bokemeyer C, Gerl A, Schoffski P, et al.: Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999, 17:512-516.
27. Einhorn LH, Stender MJ, Williams DS, et al.: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999, 17:509-511.
28. Hinton S, Catalano P, Einhorn LH, et al.: Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002, 20:1859-1863. New options for patients with cisplatin-refractory disease, even if heavily pretreated.
29. Kollmannsberger C, Rick O, Derigs HG, et al.: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002, 20:2031-2037.
30. Rosti G, Pico JL, Wandt H, et al.: High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective, randomized trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 2002, 20:716a. The first randomized, prospective data on the use of stem cell transplantation compared with salvage chemotherapy.
31. Geldart TR, Simmonds PD, Mead GM: Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 2002, 90:451-455.
32. Joly F, Heron JF, Kalusinski L, et al.: Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol 2002, 20:73-80.